NW Bio Offers 'Promising Survival Data' in 51 GBM Patients Treated with DCVAX-L: Data Demonstrated Substantially Longer-Than-Expected Survival

By: via Benzinga
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.